919 results on '"Yin, Yongmei"'
Search Results
52. Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study
53. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial
54. An Imbalance in Histone Modifiers Induces tRNA-Cys-GCA Overexpression and tRF-27 Accumulation by Attenuating Promoter H3K27me3 in Primary Trastuzumab-Resistant Breast Cancer.
55. Effectiveness and Safety of Palbociclib plus Endocrine Therapy in Patients with Advanced Breast Cancer: A Multi-Center Study in China
56. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer: a long-term safety and overall survival update from the randomised, double-blind, placebo-controlled, phase 3 trial
57. Amplified electrochemical detection of surface biomarker in breast cancer stem cell using self-assembled supramolecular nanocomposites
58. A competitive immunoassay using hapten-modified polydiacetylene vesicles for homogeneous and sensitive detection of sodium benzoate
59. Thionine mediated para-sulfonatocalix[4]arene capped AuNPs multilayers for sensitive electrochemical detection of acetylcholinesterase activity
60. Roles of tRNA-derived fragments in human cancers
61. Role of locoregional surgery in patients with de novo stage IV breast cancer: analysis of real-world data from China
62. 1,25(OH)2D3 deficiency increases TM40D tumor growth in bone and accelerates tumor-induced bone destruction in a breast cancer bone metastasis model
63. Efficacy of abemaciclib versus tucidinostat after progression on palbociclib in patients with HR+/HER2− MBC: A multicenter retrospective cohort study.
64. Mitochondria-Mediated HSP Inhibition Strategy for Enhanced Low-Temperature Photothermal Therapy
65. Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer
66. Single-cell sequencing and transcriptome analysis identified a comprehensive risk score model based on immune-related metabolic genes for improving the prediction of sensitivity in breast cancer immunotherapy
67. Abstract CT175: Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 in HER2-expressing/mutated advanced solid tumors: A global phase 1, multi-center, first-in-human study
68. Identification and validation of a novel anoikis-related signature to predict clinical outcomes, TME and treatment response of breast cancer patients
69. Abstract 3698: Epigenetic modification induced reprogramming of PUFAs-associated metabolism during trastuzumab resistance formation of HER2-positive breast cancer
70. Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR+HER2− metastatic breast cancer
71. Magnetism based electrochemical immunosensor for chiral separation of amlodipine
72. Roles of cancer/testis antigens (CTAs) in breast cancer
73. Electrochemical detection of intracellular glutathione based on ligand exchange assisted release of DNA-templated silver nanoparticles
74. A sensitive chemiluminescent immunoassay to detect Chromotrope FB (Chr FB) in foods
75. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial
76. Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population
77. Update and interpretation of CSCO guidelines in 2023: HER2-positive advanced breast cancer.
78. A one-pot strategy for the detection of proteins based on sterically and allosterically tunable hybridization chain reaction
79. Rolling circle amplification in electrochemical biosensor with biomedical applications
80. Electrochemical detection of glutathione based on Hg2+-mediated strand displacement reaction strategy
81. Abstract P4-01-21: Phase 2 Study of the CDK4/6 Inhibitor FCN-437c in Combination With Fulvestrant or Letrozole and Goserelin in Patients With HR+, HER2– Advanced Breast Cancer
82. Abstract P2-03-20: Clinical profiling and comprehensive analysis of candidate genes related to breast cancer estrogen receptor intratumour heterogeneity
83. Abstract P1-11-16: Treatment with tyrosine kinase inhibitors (TKIs) in HER2-positive metastatic breast cancer after trastuzumab emtansine (T-DM1) failure: A real-world study
84. Abstract OT1-14-01: Efficiency and safety of palbociclib in patients with locally advanced or metastatic breast cancer: a muti-center real world study
85. Abstract P1-13-20: Reprogramming of oncogenic signal pathways and metabolism during trastuzumab resistance formation of HER2 positive breast cancer
86. Abstract P3-07-04: A multicenter, single-arm, open-label Phase I study of AN1004 (Pelareorep) oncolytic virus plus paclitaxel in Chinese patients with Hormone receptor-positive and HER2-negative advanced/metastatic breast cancer (REO 026-1)
87. Abstract OT1-03-02: Efficacy and safety of SKB264 for previously treated metastatic triple negative breast cancer in Phase 2 study
88. Exosome-Transmitted tRF-16-K8J7K1B Promotes Tamoxifen Resistance by Reducing Drug-Induced Cell Apoptosis in Breast Cancer
89. Proteolytic regulation of CD73 by TRIM21 orchestrates tumor immunogenicity
90. An MMP-2 sensitive and reduction-responsive prodrug amphiphile for actively targeted therapy of cancer by hierarchical cleavage
91. Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy
92. Exosomal miR-30a-5p promoted intrahepatic cholangiocarcinoma progression by increasing angiogenesis and vascular permeability in PDCD10 dependent manner
93. METTL3-Mediated m6A Modification of PSAT1 mRNA Promotes HER2-Positive Breast Cancer Resistance to Trastuzumab
94. Enantiomeric separation of 1,4-dihydropyridines by liquid-phase microextraction with supercritical fluid chromatography
95. Preparation of polyclonal antibodies for nateglinide (NTG) and development of a sensitive chemiluminescent immunoassay to detect NTG in tablets and serum
96. A new method to evaluate trinucleotide repeats length polymorphism
97. A colorimetric ATP assay based on the use of a magnesium(II)-dependent DNAzyme
98. Prognostic value of the neutrophil to lymphocyte ratio in lung cancer: A meta-analysis
99. Sensitive colorimetric assays for α-glucosidase activity and inhibitor screening based on unmodified gold nanoparticles
100. Prospective Assessment of Pemetrexed or Pemetrexed Plus Platinum in Combination With Gefitinib or Erlotinib in Patients With Acquired Resistance to Gefitinib or Erlotinib: A Phase II Exploratory and Preliminary Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.